These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 33846962)
1. The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. Schwarz AJ Neurotherapeutics; 2021 Apr; 18(2):686-708. PubMed ID: 33846962 [TBL] [Abstract][Full Text] [Related]
2. Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Ten Kate M; Ingala S; Schwarz AJ; Fox NC; Chételat G; van Berckel BNM; Ewers M; Foley C; Gispert JD; Hill D; Irizarry MC; Lammertsma AA; Molinuevo JL; Ritchie C; Scheltens P; Schmidt ME; Visser PJ; Waldman A; Wardlaw J; Haller S; Barkhof F Alzheimers Res Ther; 2018 Oct; 10(1):112. PubMed ID: 30376881 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Blennow K; Hampel H; Zetterberg H Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530 [TBL] [Abstract][Full Text] [Related]
4. Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases. Schwarz CG Neurotherapeutics; 2021 Apr; 18(2):661-672. PubMed ID: 33723751 [TBL] [Abstract][Full Text] [Related]
5. Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review. Asken BM; Rabinovici GD Acta Neuropathol Commun; 2021 May; 9(1):96. PubMed ID: 34022959 [TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. Del Sole A; Malaspina S; Magenta Biasina A Funct Neurol; 2016; 31(4):205-215. PubMed ID: 28072381 [TBL] [Abstract][Full Text] [Related]
7. Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers. Mutlu J; Landeau B; Gaubert M; de La Sayette V; Desgranges B; Chételat G Brain; 2017 Dec; 140(12):3317-3328. PubMed ID: 29194503 [TBL] [Abstract][Full Text] [Related]
8. Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis. Hellwig S; Domschke K; Meyer PT Curr Opin Neurol; 2019 Aug; 32(4):548-556. PubMed ID: 31107281 [TBL] [Abstract][Full Text] [Related]
9. Tau-imaging in neurodegeneration. Bischof GN; Endepols H; van Eimeren T; Drzezga A Methods; 2017 Nov; 130():114-123. PubMed ID: 28790016 [TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Neuroimaging Techniques to Assist Clinical Trials on Cell-Based Therapies in Neurodegenerative Diseases. Wilson H; de Natale ER; Politis M Stem Cells; 2022 Aug; 40(8):724-735. PubMed ID: 35671344 [TBL] [Abstract][Full Text] [Related]
11. Classics in Neuroimaging: Untangling the Role of Tau in Neurodegenerative Disorders Using Positron Emission Tomography. Witek JA; Brooks AF; Scott PJH ACS Chem Neurosci; 2022 Oct; 13(19):2778-2783. PubMed ID: 36112411 [TBL] [Abstract][Full Text] [Related]
13. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942 [TBL] [Abstract][Full Text] [Related]
14. Interpretation of Biomarker Data in Diagnosis of Primary Dementias. Salardini A Semin Neurol; 2019 Apr; 39(2):200-212. PubMed ID: 30925613 [TBL] [Abstract][Full Text] [Related]
15. Positron Emission Tomography Molecular Imaging of the Major Neurodegenerative Disorders: Overview and Pictorial Essay, from a Nuclear Medicine Center's Perspective. Calabria F; Leporace M; Cimini A; Ricci M; Travascio L; Bagnato A J Integr Neurosci; 2023 Dec; 22(6):172. PubMed ID: 38176937 [TBL] [Abstract][Full Text] [Related]
16. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523 [TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
18. Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years. Kapoor A; Bartha R; Black SE; Borrie M; Freedman M; Gao F; Herrmann N; Mandzia J; Ozzoude M; Ramirez J; Scott CJM; Symons S; Fischer CE; Frank A; Seitz D; Wolf MU; Verhoeff NPLG; Naglie G; Reichman W; Masellis M; Mitchell SB; Tang-Wai DF; Tartaglia MC; Kumar S; Pollock BG; Rajji TK; Finger E; Pasternak SH; ; Swartz RH J Alzheimers Dis; 2020; 74(3):747-757. PubMed ID: 32116253 [TBL] [Abstract][Full Text] [Related]
19. Guidelines for the conduct of clinical trials in spinal cord injury: Neuroimaging biomarkers. Seif M; Gandini Wheeler-Kingshott CA; Cohen-Adad J; Flanders AE; Freund P Spinal Cord; 2019 Sep; 57(9):717-728. PubMed ID: 31267015 [TBL] [Abstract][Full Text] [Related]
20. Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative. Weiner MW; Veitch DP Alzheimers Dement; 2015 Jul; 11(7):730-3. PubMed ID: 26194308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]